Status:

COMPLETED

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Lead Sponsor:

Oregon Health and Science University

Collaborating Sponsors:

Forest Laboratories

University of Southern California

Conditions:

Multiple Sclerosis

Cognition Disorders

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

PHASE3

Brief Summary

This study is designed to determine whether memantine is an effective treatment for memory and cognitive problems associated with multiple sclerosis when compared to placebo.

Detailed Description

Objective: The objective of this pilot project is to conduct a clinical trial to assess the efficacy of memantine as a treatment for cognitive dysfunction in multiple sclerosis (MS). We hypothesize t...

Eligibility Criteria

Inclusion

  • A diagnosis of multiple sclerosis as defined by the McDonald criteria. Patients with relapsing-remitting, secondary progressive, and primary progressive forms of MS are eligible.
  • Age between 18 and 65 years.
  • Demonstrated cognitive dysfunction at screening defined as a score worse than 1.0 standard deviations below the mean on the PASAT or the CVLT-II.

Exclusion

  • A history of major depression, psychosis, or a score \> 19 on the Beck's Depression Inventory.
  • Corrected binocular visual acuity worse than 20/50; any impairment of binocular color vision.
  • Patients that do not speak English as a primary language (fluency may impact performance).
  • A clinically significant MS exacerbation within 30 days of the screening
  • Pregnancy
  • Renal insufficiency.
  • History of seizures.
  • Patients using acetazolamide (Diamox, Ak-sol, Storzolamide), dichlorphenamide (Daranide), methazolamide (Neptazane) or topiramate (Topamax), dextromethorphan (Robitussin DM and other cold remedies), or amantadine (Symmetrel).
  • Use of medical marijuana in the prior six months.
  • History of alcohol abuse or illicit drug use in the prior six months.

Key Trial Info

Start Date :

April 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2009

Estimated Enrollment :

82 Patients enrolled

Trial Details

Trial ID

NCT00300716

Start Date

April 1 2004

End Date

January 1 2009

Last Update

October 15 2019

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

USC

Los Angeles, California, United States, 90033

2

OHSU

Portland, Oregon, United States, 97201

3

UT Southwestern

Dallas, Texas, United States, 75390-9036

4

MS Hub

Seattle, Washington, United States, 98101